Comparative Pharmacology
Head-to-head clinical analysis: ENOVID E versus WOLFINA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENOVID E versus WOLFINA.
ENOVID-E vs WOLFINA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination estrogen-progestin contraceptive. Suppresses gonadotropin release, inhibits ovulation, increases cervical mucus viscosity, and alters endometrial morphology.
Not specified in available data; likely unapproved or investigational drug.
5 mg orally once daily for 20 days starting on day 5 of menstrual cycle
Initial: 50 mg orally twice daily. Titrate to 100 mg twice daily after 2 weeks based on tolerability.
None Documented
None Documented
Norethynodrel: 5-10 hours; mestranol: 2-5 hours (metabolized to ethinyl estradiol, half-life 10-20 hours). Steady-state reached in 5-7 days.
Terminal elimination half-life is 12-18 hours in healthy adults; prolonged to 24-36 hours in renal impairment (CrCl <30 mL/min), requiring dose adjustment.
Renal (50-60% as metabolites, <1% unchanged); fecal (40-50%)
Primarily renal (70% unchanged), with 20% biliary/fecal and 10% metabolic degradation.
Category C
Category C
Oral Contraceptive
Oral Contraceptive